22:50 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: B cell lymphoma Cell and mouse studies suggest promoting PMAIP1 expression or inhibiting MCL1 could enhance the efficacy of BCL-2 inhibitors to treat diffuse large B cell lymphoma (DLBCL). In a DLBCL cell line,...
20:15 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

FDA extends review of Samsung Bioepis' trastuzumab biosimilar

A Samsung Bioepis Co. Ltd. spokesperson told BioCentury that FDA extended by three months its review of a BLA for SB3, a biosimilar of cancer drug Herceptin trastuzumab from Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech...
18:10 , Nov 9, 2018 |  BC Week In Review  |  Company News

Genentech seeks to block JHL from using trade secrets

Genentech Inc. is asking a federal court to block JHL Biotech Inc. (Zhubei, Taiwan) from making and selling products the company claims benefited from its proprietary information, following the indictment of three former Genentech employees...
01:14 , Nov 9, 2018 |  BC Extra  |  Company News

FDA extends review of Samsung Bioepis' trastuzumab biosimilar

A Samsung Bioepis Co. Ltd. spokesperson told BioCentury that FDA extended by three months its review of a BLA for SB3, a biosimilar of cancer drug Herceptin trastuzumab from Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech...
00:40 , Nov 8, 2018 |  BC Extra  |  Company News

Genentech seeks to block JHL from using trade secrets

Genentech Inc. is asking a federal court to block JHL Biotech Inc. (Zhubei, Taiwan) from making and selling products the company claims benefited from its proprietary information, following the indictment of three former Genentech employees...
23:24 , Nov 7, 2018 |  BC Extra  |  Company News

Management tracks: Myovant, Alkahest

Women’s health and endocrine disease company Myovant Sciences Ltd. (NYSE:MYOV) named Kim Sablich chief commercial officer and Jeff Nornhold SVP of pharmaceutical operations and development. Sablich was VP of primary care marketing in the U.S....
19:45 , Nov 6, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cellular assays; gene profiling; tissue markers Gene profiling coupled with cell-based assays of patient samples could help predict drug responses in AML patients. In tumor samples from 363 patients, whole-exome sequencing plus genotyping of...
19:57 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

EC approves AbbVie's Venclexta in combination with Rituxan for CLL

The European Commission approved Venclyxto venetoclax in combination with Rituxan rituximab to treat relapsed/refractory chronic lymphocytic leukemia in patients who have received at least one prior therapy. Venclyxto is already approved for the indication as...
19:54 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

Genentech's faricimab improves BCVA in Phase II for wet AMD

Genentech Inc. reported data from the Phase II STAIRWAY trial to treat wet age-related macular degeneration (AMD) showing that faricimab (RG7716) dosed every 12 or 16 weeks led to sustained improvements in visual outcomes that...
19:50 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

MorphoSys reports updated ORR of 58% for MOR208 in DLBCL

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) reported that MOR208 plus Revlimid lenalidomide led to a 58% overall response rate (ORR) among 81 evaluable patients with relapsed or refractory diffuse large B cell lymphoma in the Phase II...